Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Current Deferred Revenue (2019 - 2025)

Historic Current Deferred Revenue for Nurix Therapeutics (NRIX) over the last 7 years, with Q4 2025 value amounting to $17.6 million.

  • Nurix Therapeutics' Current Deferred Revenue fell 5417.58% to $17.6 million in Q4 2025 from the same period last year, while for Nov 2025 it was $17.6 million, marking a year-over-year decrease of 5417.58%. This contributed to the annual value of $17.6 million for FY2025, which is 5417.58% down from last year.
  • Latest data reveals that Nurix Therapeutics reported Current Deferred Revenue of $17.6 million as of Q4 2025, which was down 5417.58% from $26.0 million recorded in Q3 2025.
  • Nurix Therapeutics' Current Deferred Revenue's 5-year high stood at $48.1 million during Q4 2023, with a 5-year trough of $17.6 million in Q4 2025.
  • Its 5-year average for Current Deferred Revenue is $37.2 million, with a median of $38.0 million in 2022.
  • Per our database at Business Quant, Nurix Therapeutics' Current Deferred Revenue surged by 4981.74% in 2024 and then crashed by 5417.58% in 2025.
  • Nurix Therapeutics' Current Deferred Revenue (Quarter) stood at $41.2 million in 2021, then fell by 8.68% to $37.6 million in 2022, then increased by 27.81% to $48.1 million in 2023, then dropped by 20.24% to $38.4 million in 2024, then crashed by 54.18% to $17.6 million in 2025.
  • Its last three reported values are $17.6 million in Q4 2025, $26.0 million for Q3 2025, and $27.4 million during Q2 2025.